Vincerx Pharma(US:VINC) Globenewswire·2025-01-29 13:00Core Insights - Vincerx Pharma and Oqory are highlighting the promising Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, and discussing their proposed strategic merger to advance this asset into global Phase 3 trials [1][5] Company Overview - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with a pipeline that includes next-generation ADCs and other innovative treatments [11] - Oqory, Inc. specializes in developing next-generation antibody drug conjugates (ADCs) for cancer treatment and has multiple ADC programs in clinical and preclinical stages [9] Clinical Data - OQY-3258 has shown promising results in clinical trials, including a 41% overall response rate (ORR) in patients with brain metastases and a progression-free survival (PFS) of 4.6 months compared to 2.8 months for historical data with Trodelvy [2][8] - In a Phase 3 study for unresectable recurrent or metastatic triple-negative breast cancer, OQY-3258 achieved an overall response rate of 80% in evaluable patients [4] Proposed Merger Details - The proposed merger will result in Oqory equity holders owning approximately 95% of the combined entity, with a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing [6] - The merger is contingent upon several conditions, including a concurrent private offering of at least $20 million in Vincerx equity securities and satisfactory completion of due diligence [6] Safety Profile - OQY-3258 has demonstrated a favorable safety profile, with manageable hematologic toxicities being the most common adverse events, and no Grade ≥3 rash or interstitial lung disease observed [2][8]